The Efficacy and Safety of Tofacitinib in 48 Children and Adolescents With Alopecia Areata: A Retrospective Study From China.

A single-center retrospective study evaluated tofacitinib in 48 Chinese children and adolescents (aged 2-18 years) with alopecia areata. At Week 12, the median relative improvement rate in SALT score from baseline was 50.0% (IQR: 27.2%-70.2%). By Week 24, the improvement increased to 84.3% (IQR: 52.2%-100.0%), and 20 patients (41.7%) achieved SALT100 complete response and 11 patients (22.9%) attained SALT75. During extended follow-up, 24 patients experienced relapse. Recurrence rates were significantly higher in those with dose reduction or withdrawal (73.1%, 19/26) compared to patients maintaining treatment (31.3%, 5/16). All reported adverse events were mild. Tofacitinib demonstrated efficacy and acceptable safety, but the high recurrence rate underscores the need for long-term management.